Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17)

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of Enzyme Inhibition and Medicinal Chemistry

• Publication date

  2012-07-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/14756366.2011.599323PMID 21827363
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of RGD-4C position is more important than disulfide bonds on antiangiogenic activity of RGD-4C modified endostatin derived synthetic polypeptide.

  2010cited by this paper
• An RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivo.

  2008cited by this paper
• Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases

  2007cited by this paper
• The Biochemical, Biological, and Pathological Kaleidoscope of Cell Surface Substrates Processed by Matrix Metalloproteinases

  2007cited by this paper
• The Hemopexin and O-Glycosylated Domains Tune Gelatinase B/MMP-9 Bioavailability via Inhibition and Binding to Cargo Receptors*

  2006cited by this paper
• Inhibition of lethal endotoxin shock with an L-pyridylalanine containing metalloproteinase inhibitor selected by high-throughput screening of a new peptide library.

  2006cited by this paper
• Targeting neutrophil collagenase/matrix metalloproteinase-8 and gelatinase B/matrix metalloproteinase-9 with a peptidomimetic inhibitor protects against endotoxin shock.

  2005cited by this paper
• Simulation of evolution-selected propeptide by high-throughput selection of a peptidomimetic inhibitor on a capillary DNA sequencer platform.

  2005cited by this paper
• Cleavage of denatured natural collagen type II by neutrophil gelatinase B reveals enzyme specificity, post‐translational modifications in the substrate, and the formation of remnant epitopes in rheumatoid arthritis

  2002cited by this paper
• Strategies for MMP inhibition in cancer: innovations for the post-trial era

  2002cited by this paper
• The Role of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Antibody-Induced Arthritis

  2002cited by this paper
• Biochemistry and Molecular Biology of Gelatinase B or Matrix Metalloproteinase-9 (MMP-9)

  2002cited by this paper
• Toll-like receptors: how they work and what they do

  2002cited by this paper
• Substrate Hydrolysis by Matrix Metalloproteinase-9*

  2001cited by this paper
• How matrix metalloproteinases regulate cell behavior.

  2001cited by this paper
• Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact.

  2000cited by this paper
• Tumor targeting with a selective gelatinase inhibitor

  1999cited by this paper
• Design and therapeutic application of matrix metalloproteinase inhibitors.

  1999cited by this paper
• A MATRIX METALLOPROTEINASE INHIBITOR PREVENTS PROCESSING OF TUMOR NECROSIS FACTOR α (TNFα) AND ABROGATES ENDOTOXIN‐INDUCED LETHALITY

  1997cited by this paper
• Strategies for rapid deconvolution of combinational libraries: comparative evaluation using a model system.

  1997cited by this paper
• A matrix metalloproteinase inhibitor prevents processing of tumor necrosis factor alpha (TNF alpha) and abrogates endotoxin-induced lethality.

  1997cited by this paper
• Characterization of the peptide substrate specificities of interstitial collagenase and 92-kDa gelatinase. Implications for substrate optimization.

  1994cited by this paper
• Pathogenetic mechanisms of septic shock.

  1993cited by this paper
• A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases

  1992cited by this paper
• Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8.

  1991cited by this paper
• The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family.

  1990cited by this paper
• Tissue destruction by neutrophils.

  1989cited by this paper

• Targeting marine jellyfish toxins: development of metalloproteinase inhibitors through a specific method for protease substrate identification

  2025cites this paper
• Identification and Quantitation of Bioactive and Taste-Related Dipeptides in Low-Salt Dry-Cured Ham

  2022cites this paper
• Peptide-Based Inhibitors of ADAM and ADAMTS Metalloproteinases

  2021cites this paper
• Recent developments and strategies for the discovery of TACE inhibitors

  2020cites this paper
• A fusion antitumor peptide regulates proliferation and apoptosis of endothelial cells

  2018cites this paper
• Inhibition of Neutrophil Collagenase/MMP-8 and Gelatinase B/MMP-9 and Protection against Endotoxin Shock

  2014cites this paper
• Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): The next decade

  2013influential citation
• Generation of antitumor peptides by connection of matrix metalloproteinase-9 peptide inhibitor to an endostatin fragment

  2013cites this paper
• Peptide-Based Selective Inhibitors of Matrix Metalloproteinase-Mediated Activities

  2012cites this paper